Acura shares tank on forecasted FDA delay

Acura Pharma shareholders were not the least bit happy to hear the developer announce yesterday that it was unlikely the FDA will approve Acurox--which combines niacin and oxycodone--by a June 30 deadline. Its shares tanked on the news, plunging more than 30 percent. Acura did not offer a reason why it believes the FDA won't make its deadline. "It's a data and labelling issue. I don't think they have the data to have an appropriate label," Biologic Investment Research analyst Kevin McNamara told ReutersReport

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.